Search

everythinglearnresearchcommunity

for

Search:↓

The document concludes that the 5 alpha-reductase enzymes are important in steroid metabolism and related to various human diseases, with inhibitors used to treat conditions like male pattern baldness and prostate issues.

The human type II 5α-reductase gene, linked to certain male health conditions, has a specific structure and low similarity to other related genes.

Finasteride slowly binds to 5-alpha-reductase, affecting enzyme stability and inhibitor potency.

5-alpha reductase deficiency leads to male sexual development issues and treatments like finasteride help with prostate enlargement and hair loss.

Some new progesterone derivatives are better at blocking testosterone conversion than a common drug.

Finasteride doesn't affect erections much, but may decrease libido in men.

The new compounds moderately block a specific enzyme and strongly counteract a male hormone, suggesting potential for treating certain male-related health conditions.

The main enzyme found in pubic skin that could be targeted to treat excessive hair growth is 5 alpha-R2.

Plant-based compounds might be a promising alternative for prostate cancer treatment with fewer side effects.

Finasteride, a drug that changes testosterone to a different hormone, was studied and its effects over time were modeled successfully.

The developed model can predict effective 5-alpha-reductase enzyme inhibitors.

Some plant-based products might treat hair loss with fewer side effects than current medications.

New liposome treatment successfully delivers CRISPR to deactivate a key enzyme in androgen-related disorders.

Finasteride and dutasteride are effective in treating male hair loss but can cause sexual side effects and birth defects.

5 Alpha-Reductase Inhibitors reduce the effects of testosterone by blocking its conversion into a stronger form.

5-alpha reductase inhibitors may have additional effects on cancer, mental health, heart health, and hormone levels beyond treating prostate enlargement.

Finasteride effectively treats hair loss and prostate issues with minimal side effects.

LY191704 is a compound that effectively blocks a specific enzyme involved in hormone conversion and could help treat enlarged prostate and hair loss.

A certain mutation in the fetal alpha 5-reductase gene is linked to a higher risk of late miscarriage.

The human type II 5α-reductase gene has a specific structure important for understanding certain medical conditions.

New pregnane derivatives are effective at inhibiting an enzyme linked to hair loss and reducing oil gland activity.

Finasteride works better than Permixon in reducing dihydrotestosterone levels.

Inhibitors of the enzyme 5 alpha-reductase could potentially treat disorders like prostate cancer and baldness.

Spironolactone reduces the enzyme activity that converts testosterone to DHT, helping treat excessive hair growth in women.

Selective non-steroidal inhibitors of 5α-reductase type 1 can help treat DHT-related disorders.

A new drug, dutasteride, is at least as effective as the older drug, finasteride, for treating enlarged prostate and may have additional uses.

5-alpha-reductase inhibitors may cause a low incidence of erectile dysfunction that decreases over time.

Finasteride reduces dihydrotestosterone, increases testosterone, and may treat hirsutism in women.

Some cannabinoid derivatives may be more effective than current drugs at targeting proteins relevant to prostate cancer treatment.

A new method was created to test the effectiveness of Dihydrotestosterone (DHT) inhibitors, like finasteride and dutasteride, in human and fish cells. The results showed fish cells are more sensitive to these treatments, and dutasteride works better than finasteride in all tested cells.